Resultados de la búsqueda 191-200 of 12515 for Severe hyponatraemia

1. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

2. Neurología - Ensayos clínicos - Mayo Clinic

   VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, ...

3. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

6. Hematología - Ensayos clínicos - Mayo Clinic

   The Effects Of Acute And Chronic Exercise On Immune Phenotype Of Indolent Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia Patients. Rochester, Minn ...

7. Mayo Clinic Digestive Diseases Physician Update - October 2025

   Page 1.

8. Mayo Clinic Physician Update - August 2022

   Page 1.

9. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

10. Mayo Clinic Digestive Diseases Physician Update e-Edition, June 2015

    Bile acid malabsorption (BAM)) occurs in about 1 in 3 patients with IBS-D and up to 50 percent of those with functional diarrhea, yet it remains underdiagnosed.